Clinical trial
Disitamab Vedotin Combined With Cisplatin for Neoadjuvant Therapy in Locally Advanced Cervical Cancer: a Prospective, Single-arm Clinical Trial
NCT06558682 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Disitamab Vedotin Combined With Cisplatin for Neoadjuvant Therapy in Locally Advanced Cervical Cancer: a Prospective, Single-arm Clinical Trial
- Lead sponsor
- Qilu Hospital of Shandong University
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- October 20, 2024
- Completion date
- October 1, 2026
- Enrollment
- 48 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.